North America Point-Of-Care Diagnostics Market – Industry Trends and Forecast to 2031

북미 진료 시점 진단 시장 분석 및 규모

현장 진단 시장은 환경 모니터링 및 공중 보건에서 이러한 진단의 중요성이 커짐에 따라 상당한 성장을 경험할 것으로 예상됩니다. NIH, 빌 & 멜린다 게이츠 재단과 같은 사설 재단, 미국 국방부와 같은 출처의 자금 지원이 증가하면서 제조업체는 현장 진단 장비 생산 역량을 강화할 수 있게 되었습니다.

Data Bridge Market Research는 2023년에 186억 2천만 달러였던 북미 진료 시점 진단 시장을 분석했으며, 2031년까지 301억 2천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지 예측 기간 동안 연평균 성장률은 6.20%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화      

시장 정의

진료소 진단은 조기 감염 탐지에 사용되는 빠르고 민감한 방법입니다. 외래 환자, 의사, 임상 실험실 및 가정 건강 관리 시설에 비용 효율적인 솔루션을 제공합니다. 이 접근 방식은 조기 질병 진단을 용이하게 하여 신속한 의학적 결정을 내리고, 신속한 치료 시작을 통해 건강 결과를 개선합니다.

북미 진료 시점 진단 시장 역학

운전자

• 기술의 발전으로 향상된 진단 기능 제공

소형화된 장치, 고급 센서, 최첨단 바이오센서와 같은 지속적인 혁신은 더 빠르고 정확한 질병 탐지에 기여합니다. 이러한 기술적 진보는 의료 전문가에게 효율적인 도구를 제공하여 신속한 현장 진단을 가능하게 합니다. 진료 시점 환경이 진화함에 따라 최첨단 기술의 통합은 검사 정확도를 개선하고 빠르고 정확한 진단 솔루션에 대한 증가하는 수요를 해결함으로써 시장의 성장을 지원합니다.

• 감염성 질환의 증가로 인해 신속한 진단 솔루션에 대한 필요성이 커짐

감염 발생률이 증가함에 따라 신속하고 정확한 진단 솔루션이 필요하여 치료를 신속하게 시작할 수 있습니다. 진료소 진단은 특히 감염성 질환 부담이 높은 지역에서 시기적절하고 효율적인 질병 탐지 수단을 제공합니다. 신속하고 현장에서 진단할 수 있는 도구에 대한 수요가 증가함에 따라 의료 시스템이 감염성 위협을 조기에 탐지하고 억제하기 위한 효과적인 전략을 모색함에 따라 시장이 앞으로 나아갑니다.

기회

• 비전염성 질환에 대한 강조 증가로 진단 시장 성장 증가

당뇨병, 심혈관 질환, 암과 같은 만성 질환의 유병률이 증가함에 따라 빠르고 접근 가능한 진단 도구에 대한 필요성이 커지고 있습니다. 진료 시점 진단은 NCD를 탐지하고 모니터링하는 빠르고 효율적인 수단을 제공하여 시기적절한 개입과 개인화된 치료 전략을 가능하게 합니다. NCD에 대한 이러한 집중은 진료 시점 솔루션에 대한 수요를 촉진하여 만성 질환이 제기하는 과제를 해결하는 진단 시장 확대에 기여합니다.

• 원격 환자 모니터링은 집에서 특정 검사를 제공합니다 

Enabling individuals to conduct specific tests in the comfort of their homes, this approach enhances accessibility to healthcare. Remote monitoring devices, coupled with diagnostic capabilities, empower patients to conveniently perform tests, promoting early detection and proactive management of health conditions. This trend fosters patient engagement and contributes to the overall growth of the point-of-care diagnostics market by expanding its reach beyond traditional healthcare settings.

Restraints/Challenges

• Regulatory Challenges Effecting Seamless Operations

Stringent regulatory requirements and approval processes can lead to delays in product launches and market entry. Compliance complexities and evolving regulatory landscapes may pose hurdles for companies in achieving swift and efficient commercialization of point-of-care diagnostic technologies. These challenges may impact the market's growth by creating barriers to the timely introduction of innovative solutions and hindering the operational fluidity in the industry.

• Economic Constraints Limits the Affordability of Point-of-care Diagnostic Devices

The high initial costs and ongoing expenses associated with these advanced technologies may hinder their widespread adoption, particularly in resource-constrained settings. Limited financial resources within healthcare systems and among end-users could impede the accessibility of point-of-care diagnostic solutions, potentially slowing down market growth.

This North America point-of-care diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the North America point-of-care diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2023, QIAGEN achieved CE certification for its IVD kit and NeuMoDx automated testing platform. This certification significantly bolstered the company's market share and revenue, marking a positive stride in the adoption of their advanced diagnostic technologies
• In 2023, Danaher Corporation introduced the Dxl 9000 Access Immunoassay Analyzer, capable of running up to 215 tests per hour. This strategic initiative expanded Danaher's portfolio in the point-of-care diagnostics sector, emphasizing increased testing efficiency and contributing to the company's market presence
• In 2022, Genes2Me Pvt. Ltd launched the Rapi-Q Point of Care RT PCR solution, targeting human papillomavirus (HPV) and tuberculosis. The device, with CE-IVD marking, offers rapid results in less than 45 minutes, displaying superior performance, high sensitivity, and user-friendly features
• In 2022, LumiraDx Healthcare launched its highly sensitive C-Reactive Protein (CRP) point-of-care antigen test in India. This innovative diagnostic tool addresses clinical settings' needs, aiding in the reduction of unnecessary antibiotic prescribing to combat antimicrobial resistance (AMR)
• In 2022, Genes2Me Pvt. Ltd, also launched the Rapi-Q Point of Care RT PCR solution for HPV and tuberculosis. Featuring CE-IVD marking, this device stands out for its simplicity, delivering rapid results in under 45 minutes, coupled with superior sensitivity and stable detection capabilities

North America Point-Of-Care Diagnostics Market Scope

The North America point-of-care diagnostics market is segmented on the basis of product, platform, prescription and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Glucose Monitoring Products
• Strips
• Meters
• Lancets
• Lancing Device
• Cardio metabolic
• Cardiac marker
• Blood Gas
• Electrolytes
• HBA1C
• Infectious Disease
• Influenza
• HIV
• Hepatitis C
• Sexually Transmitted Disease (STD)
• Healthcare-Associated Infection (HAI)
• Respiratory Infection
• Tropical Disease
• Other Infectious Disease
• Coagulation
• PT or INR
• Activated clotting time (ACT or APTT)
• Pregnancy and Fertility
• Pregnancy Test
• Fertility Test
• Tumour or Cancer Marker
• Urinalysis
• Cholesterol
• Haematology
• Drugs-of-Abuse
• Fecal Occult
• Others

Platform

• Lateral Flow Assays
• Immunochromatography Tests
• Dipsticks
• Microfluidics
• Molecular Diagnostics
• Immunoassays

Prescription

• Prescription-Based Testing
• OTC Testing

End User

• Clinical Laboratories
• Outpatient Healthcare and Ambulatory Care Settings
• Hospitals or Critical Care Centres
• Home Care
•  Research Laboratories
• Others

North America Point-Of-Care Diagnostics Market Regional Analysis/Insights

The North America point-of-care diagnostics market is analyzed and market size insights and trends are provided by product, platform, prescription and end user as referenced above.

The major countries covered in the North America point-of-care diagnostics market report are U.S., Canada and Mexico

The U.S. is expected to grow with the CAGR in the forecast period, primarily attributed to a surge in COVID-19 cases. The heightened demand for point-of-care diagnostics is driven by the pandemic's impact. Furthermore, a growing awareness of self-testing and home care products is poised to contribute significantly to the expansion of the North America point-of-care diagnostics market, reflecting a broader trend toward decentralized and accessible healthcare solutions.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The North America point-of-care diagnostics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for North America point-of-care diagnostics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the North America point-of-care diagnostics market. The data is available for historic period 2016-2021.

Competitive Landscape and North America Point-Of-Care Diagnostics Market Share Analysis

The North America point-of-care diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to North America point-of-care diagnostics market.

Key players operating in the North America point-of-care diagnostics market include:

• Abbott. (U.S.)
• Danaher Corporation (U.S.)
• B.D. (U.S.)
• QIAGEN (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Johnson & Johnson Private Limited (U.S.
• BIOMÉRIEUX (France)
•  Trividia Health, Inc (U.S.)
• Siemens Healthcare GmbH (Germany)
• QuidelOrtho Corporation (U.S.)
• Spectral Medical Inc (Canada)
• Abaxis (U.S.)
• Nova Biomedical (U.S.)
• Trinity Biotech (Ireland)
• Alfa Scientific Designs, Inc (U.S.)
• Bio-Rad Laboratories, Inc (U.S.) 

SKU-1810